PKM and neoplasm: The results of our meta-analysis suggest that over-expression of PKM2, which indicates a higher rate of glycolysis in tumor cells, is associated with an unfavorable prognosis and is a potential biomarker associated with OS and DFS/PFS/RFS in patients with solid tumors.